ATMI — Q2 2013 Earnings Presentation
16 slides from ATMI's earnings presentation, Jul 24, 2013
Slide 1: Q2 2013 Earnings Teleconference
Q2 2013 Earnings Teleconference July 24, 2013 hts reserved. @ ATM
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harb
Slide 3: Save The Date: ATMI Analyst Day
Save The Date ATMI Analyst Day Thursday, November 21, 2013 New York, NY For additional information contact: Troy Dewar, CFA Director, Investor Relations and Corporate Communications 203.207.9349 tdewar@atmi.com http://investor.atmi.com 2013A7M, Inc. Alrights reserved. @ ATM T°
Slide 4: Q2 2013 Summary
Q2 2013 Summary > Revenues up 3% Q/Q, but down 4% Y/Y primarily due to lower Microelectronics revenues on mixed demand environment + Tepid wafer start environment * Strong foundry demand offset by weakness at key logic accounts + Continuation of trends faced over last several quarters > LifeSciences
Slide 5: Grow the business
Grow the business * Microelectronics — win advanced nodes at key semiconductor accounts * LifeSciences — leverage intellectual property and technology in biopharmaceutical industry adoption of single-use technology * eVOLV™ — sign additional license agreements in H213; royalty revenues beginning H21
Slide 6: Q2 2013 Revenues by Segment
$M (except per Q2 2013 Revenues by Segment share data) Microelectronics 88% 102.0 Gross profit 48.7 Gross margin 47.7% Revenue mLifeSciences 12% Operating income 12.7 Q2 2013 Revenues by Geography Asia 70% Operating margin 12.5% 9.4 $0.29 North America 18% Net income Q2 2013 Earnings Teleconference
Slide 7: Microelectronics
Microelectronics Q2 2013 Microelectronics Revenues by Product m Implant 32% Cu Materials 49% Mi Liquid Packaging 14% mOther 5% Q2 2013 Microelectronics om Revenues by Sector Revenues Gross margin Operating income 26.9 Operating margin 30.0% m Memory 26% Logic 67% = Flat Panel Display 7% Q2 2013 Earn
Slide 8: LifeSciences
LifeSciences Q2 2013 LifeSciences Revenues by Product Revenues 11.9 115. SUT Consumables 35% . SUT Equipment 13% Gross margin 38% 36% eariipae Operating income — (1.7) (1.3) (11.2%) m Sterile Packaging 44% Operating margin (14.1%) Q2 2013 Earnings Teleconference > Record revenues on Y/Y increase in
Slide 9: Other Financial Data
Q2 2013 Earnings Teleconference Other Financial Data Q2 2013 2012 Q1 2013 Cash and marketable securities 124.6 107.9) 151.1 Cash from (used for) operating activities 9.6 7) (6.2) Capital Expenditures 15.3 5.3 8.5 Depreciation & Amortization 7.2 6.6 wa Headcount 850 823 828 > Cash balance down due to
Slide 10: Capital Allocation Strategy
Capital Allocation Strategy > Sources of cash and liquidity + Operations: objective to generate ~$20M per quarter * Balance sheet > Cash balance: $125M at end of Q2 2013 > Debt capacity high given no existing leverage > Uses of cash + Run the business — working capital; maintenance capital expenditu
Slide 11: Outlook
a g 2 g g € oO 8 8 z a % £ € Fs & ” g So g N (of Outlook > Microelectronics * Tempered wafer starts outlook; full-year 2013 wafer starts up minimally * Margin improvement through volume and mix benefit > LifeSciences * Confident in our long-term revenue CAGR of 20-30% * GM improving through volume b
Slide 12: Thank you for your interest
@ ATM! Thank you for your interest. For additional information contact: Troy Dewar, CFA Director, Investor Relations and Corporate Communications 203.207.9349 tdewar@atmi.com http://investor.atmi.com ATMIand the ATMI logo are trademarks or registered trademarks of Advanced ©2013A7M ne Aehsresere, @
Slide 13: Appendix
Appendix
Slide 14: ATMI — enabling Process Efficiency gains for our customers
a g 2 g g € oO 8 8 z a % £ € Fs & ” g So g N (of ATMI —a technology company enabling Process Efficiency gains for our customers Revenues ($M) $367 $390 $407 $410 2010 2011 2012 =Q2 2013 LTM Operating Income ($M)* Si $47 $59 $59 2010 2011 2012 Q2 2013 LT™M “Excludes $84.6M charge for contract termina
Slide 15: Microelectronics — enabling technology for semiconductor manufacturing
a g 2 g g € oO 8 8 z a % £ € Fs & ” g So g N (of Microelectronics — enabling technology for semiconductor manufacturing Revenues ($M) $336 $351 $366 $365 2010 2011 2012) Q2 2013 LTM Operating Income ($M)* $04 $98 $109 $110 2010 2011 2012 =Q2 2013 L™ “Excludes $84.6M charge for contract termination i
Slide 16: LifeSciences — trusted single-use technology partner
LifeSciences — trusted single-use technology partner Revenues ($M) Pa Serving oe - cutting-edge life science applications so 7 oe $31 > Enables product development life cycle optimization > Creates entirely new market segment 2010 2011 2012 Q22013 > Single-use technology (SUT) products Sterile Packa